<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624283</url>
  </required_header>
  <id_info>
    <org_study_id>vestibular rehabilitation</org_study_id>
    <nct_id>NCT03624283</nct_id>
  </id_info>
  <brief_title>Interventions for Residual Dizziness After Successful Repositioning Maneuvers in Patients With BPPV</brief_title>
  <official_title>The Effect of Vestibular Exercise, With or Without Medication, in Managing Residual Dizziness After Successful Repositioning Maneuvers in Patients With Benign Paroxysmal Positional Vertigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of vestibular rehabilitation, with or without medication, on
      resolving residual dizziness after successful repositioning maneuvers in patients with benign
      paroxysmal positional.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Balance function</measure>
    <time_frame>Change from baseline, at 4 weeks, 8 weeks and 12 weeks postrandomisation</time_frame>
    <description>Balance function, measured by computerized dynamic posturography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of RD symptoms</measure>
    <time_frame>Change from baseline at 4 weeks, 8 weeks and 12 weeks postrandomisation.</time_frame>
    <description>Patients self-reported days for RD onset to disappear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment scale</measure>
    <time_frame>Change from baseline at 4 weeks, 8 weeks and 12 weeks postrandomisation.</time_frame>
    <description>Measured by Dizziness and Handicap Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Otolith function</measure>
    <time_frame>Change from baseline at 4 weeks, 8 weeks and 12 weeks follow-up will be necessary only when the previous examine showing abnormal.</time_frame>
    <description>Analyzed as vestibular evoked myogenic potenials (VEMPs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily function</measure>
    <time_frame>Change from baseline, at 4 weeks, 8 weeks and 12 weeks postrandomisation</time_frame>
    <description>Daily function quantified by Vestibular Activities and Participation (VAP) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Vestibular Disorder</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C will receive an combination of Exercise-based VR plus Betahistine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betahistine</intervention_name>
    <description>Betahistine is used in the treatment of and vertigo.</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise-based vestibular rehabilitation</intervention_name>
    <description>Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed as unilateral BPPV (unilateral posterior semicircular canal BPPV or
             horizontal semicircular canal BPPV) according to the clinical practice guideline
             issued by American Academy of Otolaryngology and head and neck surgery (AAO-HNSF) in
             2017;

          2. Aged 18~80 years;

          3. Reporting residual symptoms after successful repositioning maneuvers;

        Exclusion Criteria:

          1. Anterior semicircular canal BPPV or multicanal BPPV;

          2. Recurrent BPPV;

          3. Subjects with coexisting vestibular disorders, including Meniere disease, vestibular
             neuritis, labyrinthitis, and peripheral vestibular loss;

          4. Subjects with severe cervical spine disease;

          5. Subjects with severe cardiovascular diseases ;

          6. Subjects with known cerebral vascular disease like carotid stenosis;

          7. Cognitive impairment;

          8. Suspect of significant depression or anxiety as defined as a score of â‰¥ 8 for each
             respective scale of Hospital anxiety and depression scale;

          9. Pregnant/ lactating or planning to become pregnant during the study period;

         10. Had taken vestibulosupressant, antihistamines, and/ or ototoxic medications in the
             past 3 months;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huawei Li</last_name>
    <phone>+86-13524844652</phone>
    <email>hwli@shmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peixia Wu</last_name>
    <email>13524844652@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Otorhinolaryngology Department of Affiliated Eye and ENT Hospital, Fudan University, Shanghai, China</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huawei Li, Phd &amp;MD</last_name>
      <email>hwli@shmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Peixia Wu, MS &amp;MD</last_name>
      <email>13524844652@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 12, 2018</last_update_submitted>
  <last_update_submitted_qc>August 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye &amp; ENT Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Huawei Li, Ph.D, MD</investigator_full_name>
    <investigator_title>Director of Otorhinolaryngology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vestibular Diseases</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betahistine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

